While the immunomodulator ATYR1940 was unsuccessful in a clinical trial for FSHD, it is feasible that an anti-inflammatory treatment in combination with a DUX4-targeting therapy might be effective at halting disease progression and restoring a healthy muscle environment. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.